Post on 03-Jan-2016
description
transcript
Towards an Industry Advisory GroupAn Open Round-Table Conversation
19 May 2009
Do not copy or reproduce without express written permission of Foresight Group, LLC (Foresight). For more information, contact Foresight at info@foresight-grp.com. Or visit our website: www.foresight-grp.com
ConfidentialDo not copy or reproduce without express written permission of Foresight Group, LLC (Foresight). For more information, contact Foresight at info@foresight-grp.com. Or visit our website: www.foresight-grp.com c 2
Towards an Industry Advisory Group – An Open Round-Table Conversation
Faced with the product design, manufacturing, marketing and sales restrictions and requirement as well as new reporting and documentation requirements to be mandated under a new regulatory regime, what should companies be doing now to prepare their organizations and their consumers?
ConfidentialDo not copy or reproduce without express written permission of Foresight Group, LLC (Foresight). For more information, contact Foresight at info@foresight-grp.com. Or visit our website: www.foresight-grp.com c
Purpose & Objectives of Today’s Discussion
Facilitate preliminary discussion of guiding principles for the tobacco industry as it enters a new era of regulation
Encourage active participation and presentation of differing viewpoints
Lay groundwork for future discussions and industry actions
3
Ultimately, agreement on a set of actionable guiding principles will allow the tobacco industry to better adapt and respond to the challenges of a new and ever-evolving regulatory environment.
ConfidentialDo not copy or reproduce without express written permission of Foresight Group, LLC (Foresight). For more information, contact Foresight at info@foresight-grp.com. Or visit our website: www.foresight-grp.com c
Panel Members
Name Affiliation
Farrell Delman (moderator) Tobacco Merchants Association
Terry Gallagher Smoker Friendly
Bill Greiwe Cheyenne Tobacco
Bill Godshall Smokefree Pennsylvania
Brian Haynes Troutman Sanders
John Lauterbach Lauterbach & Associates
John Manthei Latham Watkins
David O’Reilly BAT
Adrian Payne Tobacco Horizons
Roger Penn Mane France
Jamie Portnoff Foresight Group
Jim Starkey Tobacco Merchants Association
Jim Swauger RAI
Lyle Smith DLC Services
Uwe Trinks Foresight Group
ConfidentialDo not copy or reproduce without express written permission of Foresight Group, LLC (Foresight). For more information, contact Foresight at info@foresight-grp.com. Or visit our website: www.foresight-grp.com c
What Companies Should be Doing Now
Required actions can be organized in three major categories:
5
The following slides will examine these topics in more detail
ConfidentialDo not copy or reproduce without express written permission of Foresight Group, LLC (Foresight). For more information, contact Foresight at info@foresight-grp.com. Or visit our website: www.foresight-grp.com c
“Regulatory Response”
FDA and other health authorities will publish proposed regulations and guidelines and solicit stakeholder feedback
Stakeholders, including tobacco manufacturers, will have the opportunity to provide written responses to the health authorities
Tobacco can chose to either respond using the pharma industry approach or take an alternative approach
6
Traditional Pharma approach - Each individual manufacturer develops their own interpretation/application of the proposed rules, and submits their own written response to health authorities
Alternative approach – Single task force composed of representatives from all manufacturers collectively discuss proposed rules and potential implications for industry, and coordinate a single written response to health authorities
ConfidentialDo not copy or reproduce without express written permission of Foresight Group, LLC (Foresight). For more information, contact Foresight at info@foresight-grp.com. Or visit our website: www.foresight-grp.com c
“Regulatory Affairs Strategy” (1)
Waxman Bill includes requirement for initial and periodic registration of new and existing individual tobacco products and their ingredients, including a description of tobacco, substances, compounds, and additives, including nicotine content and smoke constituents, by brand and sub-brand
Documents that relate to health, toxicological, behavioral, or physiologic effects of current or future tobacco products, their constituents (including smoke constituents), ingredients, components, and additives would also require submission to health authorities
In order to bring a “modified risk product” to market, a detailed product application will need to be submitted; following approval, the applicant will need to conduct post-marketing surveillance
7
Each tobacco manufacturer will need to evaluate how proposed regulations will impact their overall product strategies in both the near- and long-term
ConfidentialDo not copy or reproduce without express written permission of Foresight Group, LLC (Foresight). For more information, contact Foresight at info@foresight-grp.com. Or visit our website: www.foresight-grp.com c
“Regulatory Affairs Strategy” (2)
Specific regulatory strategies will need to be developed, and these should take into account:
Current regulatory landscape Anticipated future regulatory landscape Emerging public policies Available regulatory pathways for approval Achievable commercial claims/target labeling Potential regulatory and/or product risks Possibility of accelerated development or exclusivity
Industry will need to anticipate how the new regulatory environment will impact timelines to:
Bring a new or modified product to market Efficiently and accurately register existing products with FDA
Is all required information available to fulfill this requirement? Can planned product launches continue to market on schedule?
8
ConfidentialDo not copy or reproduce without express written permission of Foresight Group, LLC (Foresight). For more information, contact Foresight at info@foresight-grp.com. Or visit our website: www.foresight-grp.com c
“Regulatory Affairs Strategy” (3)
Stakeholders in establishment of regulatory affairs strategy: Regulatory affairs Clinical development Pharmacovigilance/drug safety Pre-clinical Sales/Marketing Manufacturing
9
ConfidentialDo not copy or reproduce without express written permission of Foresight Group, LLC (Foresight). For more information, contact Foresight at info@foresight-grp.com. Or visit our website: www.foresight-grp.com c
“Regulatory Readiness” (1) Industry needs to assess their organizational, functional and technical needs
following interpretation of proposed regulations New technical solutions will be required for:
Safety reporting - for adverse events reported by consumers Product complaint tracking/investigation – for product complaints reported by
consumers Product registration information- to manage information communicated to health
authorities Corrective action/Preventative action tracking
Existing technical solutions will need to undergo a functional technical assessment
10
Traditional Pharma approach - Each individual manufacturer performs their own assessment and buys/builds their own technical solutions
Alternative approach - Industry performs collective assessment and establishes “global” technical industry standards and “industry technical solutions” that do not constitute a competitive advantage
ConfidentialDo not copy or reproduce without express written permission of Foresight Group, LLC (Foresight). For more information, contact Foresight at info@foresight-grp.com. Or visit our website: www.foresight-grp.com c
“Regulatory Readiness” (2)
Functional areas will need to be established and/or enhanced: Manufacturing Clinical development Pharmacovigilance Regulatory Affairs
Tobacco manufacturers should be prepared to comply with: Good Clinical Practices Good Manufacturing Practices Good Pharmacovigilance Practices
11
ConfidentialDo not copy or reproduce without express written permission of Foresight Group, LLC (Foresight). For more information, contact Foresight at info@foresight-grp.com. Or visit our website: www.foresight-grp.com c
“Regulatory Readiness” – Pharma Experience
Pharma has had mixed success with the collective approach, due to several factors: Pharma can be “slow–moving” with regard to adopting new approaches Efforts to work collaboratively were initiated after each manufacturer
already began to work independently Successful efforts to date have had a tremendously positive impact
on business efficiencies
12